Highlights the unique advantages its DCT solutions hold for small to mid-size biotechs conducting trials for complex diseases
Advances commitment to support patient needs across diverse populations
Veristat’s Bold Thinking and World Class Clinical, Regulatory and Commercialization Capabilities Allow the Company to Successfully Tackle Complex Therapy Development Challenges to Meet the Goals of its Clients
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder
Instrumental to Veristat’s growth, success, and client satisfaction over the last 15 years
Providing sponsors expert staff to accelerate milestones and support study success
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments
Accomplished Financial Executive to Drive Company’s Next Phase of Growth
Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases